Form 4: RA Capital Management Reports Beneficial Ownership Changes in Tyra Biosciences, Inc.

RA Capital Management and related entities report acquisition of stock options in Tyra Biosciences, Inc. pursuant to a non-employee director compensation program.

Summary

• RA Capital Management, L.P., along with related entities and individuals, filed a Form 4 detailing changes in beneficial ownership of Tyra Biosciences, Inc. (TYRA) securities.
• The report indicates the acquisition of stock options by Jake Simson, a Partner of RA Capital Management, pursuant to Tyra Biosciences' Non-Employee Director Compensation Program.
• The options, representing the right to buy 18,600 shares of common stock at an exercise price of $15.94, were granted on May 29, 2024.
• The options vest monthly over a 12-month period following the grant date, with potential for accelerated vesting upon the next annual meeting of Tyra Biosciences' stockholders.
• RA Capital Management, RA Capital Healthcare Fund, RA Capital Nexus Fund, Peter Kolchinsky, and Rajeev Shah disclaim beneficial ownership of the reported securities except to the extent of their pecuniary interest.
• Mr. Simson holds the option for the benefit of the Fund, the Nexus Fund, and the Account and is obligated to turn over any net cash or stock received upon exercise of the option to offset advisory fees.

Sentiment

Score: 6

Explanation: The sentiment is neutral as the document primarily reports a routine transaction. The grant of stock options to a director is a common practice and doesn't inherently indicate positive or negative sentiment.

Positives

• The acquisition of stock options indicates continued alignment of interests between RA Capital Management and Tyra Biosciences.
• The vesting schedule incentivizes long-term engagement and performance.

Future Outlook

The document does not contain specific forward-looking statements regarding Tyra Biosciences' future performance.

Industry Context

Form 4 filings are standard disclosures required by the SEC to provide transparency regarding the ownership positions and transactions of company insiders, including directors and significant shareholders. This filing indicates RA Capital Management's ongoing investment and involvement with Tyra Biosciences.

Comparison to Industry Standards

• Stock option grants to non-employee directors are a common practice in the biotechnology industry to align their interests with those of shareholders.
• The vesting schedule of 12 months is fairly standard for such grants.
• RA Capital's involvement as a significant shareholder and board member is typical for venture capital and private equity firms investing in biotech companies, similar to firms like OrbiMed Advisors or Third Rock Ventures.

Stakeholder Impact

• The stock option grant aligns the director's interests with those of shareholders, potentially encouraging decisions that increase shareholder value.

Key Dates